Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038904 · ClinicalTrials.gov registry record · Phase 2
Preventing Anaphylaxis With Acalabrutinib
A Phase 2 study of Food Allergy and Food Allergy Peanut, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05038904 is a Phase 2 study of Food Allergy and Food Allergy Peanut that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants, below the 964-participant average among 17 other Food Allergy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05038904, a Phase 2 study of Food Allergy and Food Allergy Peanut, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.
Conditions Studied
Interventions
- DRUG Acalabrutinib
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05038904
The ClinicalTrials.gov registry entry for NCT05038904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 964-participant average among 17 other Food Allergy trials with a reported enrollment target (99% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Food Allergy appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib is the first listed.
NCT05038904 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05038904 about?
NCT05038904 is a clinical study titled "Preventing Anaphylaxis With Acalabrutinib". Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to ...
What is the current status of trial NCT05038904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-12-16. Estimated completion is 2022-12-31.
What conditions does trial NCT05038904 study?
This clinical trial studies the following conditions: Food Allergy, Food Allergy Peanut.
What interventions are being tested in trial NCT05038904?
The interventions under investigation include: Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT05038904?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05038904 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.